Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Clin Med ; 12(4)2023 Feb 04.
Article in English | MEDLINE | ID: covidwho-2225419

ABSTRACT

(1) The use of high-flow nasal cannula (HFNC) combined with frequent respiratory monitoring in patients with acute hypoxic respiratory failure due to COVID-19 has been shown to reduce intubation and mechanical ventilation. (2) This prospective, single-center, observational study included consecutive adult patients with COVID-19 pneumonia treated with a high-flow nasal cannula. Hemodynamic parameters, respiratory rate, inspiratory fraction of oxygen (FiO2), saturation of oxygen (SpO2), and the ratio of oxygen saturation to respiratory rate (ROX) were recorded prior to treatment initiation and every 2 h for 24 h. A 6-month follow-up questionnaire was also conducted. (3) Over the study period, 153 of 187 patients were eligible for HFNC. Of these patients, 80% required intubation and 37% of the intubated patients died in hospital. Male sex (OR = 4.65; 95% CI [1.28; 20.6], p = 0.03) and higher BMI (OR = 2.63; 95% CI [1.14; 6.76], p = 0.03) were associated with an increased risk for new limitations at 6-months after hospital discharge. (4) 20% of patients who received HFNC did not require intubation and were discharged alive from the hospital. Male sex and higher BMI were associated with poor long-term functional outcomes.

2.
Clin Lung Cancer ; 23(6): e362-e376, 2022 09.
Article in English | MEDLINE | ID: covidwho-1819457

ABSTRACT

BACKGROUND: Due to the coronavirus disease 2019 (COVID-19) pandemic, patients may encounter lung cancer care delays. Here, we sought to examine the impact of extended treatment delay for stage III-IV non-small-cell lung cancer on patient survival. MATERIALS AND METHODS: Using National Lung Screening Trial (NLST) and National Cancer Data Base (NCDB) data, Cox regression analysis with penalized smoothing splines was performed to examine the association between treatment delay and all-cause mortality for stage III-IV lung adenocarcinoma and squamous cell carcinoma. In the NCDB, propensity score-matched analysis was used to compare cumulative survival in patients who received "early" versus "delayed" treatment (ie, 0-30 vs. 90-120 days following diagnosis). RESULTS: Cox regression analysis of the NLST (n = 392) and NCDB (n = 275,198) cohorts showed a decrease in hazard ratio the longer treatment was delayed. In propensity score-matched analysis, no significant differences in survival were found between early and delayed treatment for patients with stage IIIA, IIIB (T3-4,N2,M0), IIIC, and IV (M1B-C) adenocarcinoma and patients with IIIA, IIIB, IIIC, and IV squamous cell carcinoma (all log-rank P > .05). For patients with stage IIIB (T1-2,N3,M0) and stage IV (M1A) adenocarcinoma, delayed treatment was associated with improved survival (log-rank P = .03, P = .02). The findings were consistent in sensitivity analysis accounting for wait time bias. CONCLUSION: In this national analysis, for patients with stage III-IV adenocarcinoma and squamous cell carcinoma, an extended treatment delay by 3 to 4 months was not associated with significantly decreased overall survival compared to prompt treatment. These findings can be used to guide decision-making during the ongoing COVID-19 pandemic.


Subject(s)
Adenocarcinoma , COVID-19 , Carcinoma, Non-Small-Cell Lung , Carcinoma, Squamous Cell , Lung Neoplasms , Adenocarcinoma/epidemiology , Adenocarcinoma/mortality , Adenocarcinoma/therapy , COVID-19/epidemiology , Carcinoma, Non-Small-Cell Lung/epidemiology , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/therapy , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/therapy , Humans , Lung Neoplasms/epidemiology , Lung Neoplasms/mortality , Lung Neoplasms/therapy , Neoplasm Staging , Pandemics
3.
Clin Imaging ; 86: 83-88, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1803771

ABSTRACT

PURPOSE: To assess radiology representation, multimedia content, and multilingual content of United States lung cancer screening (LCS) program websites. MATERIALS AND METHODS: We identified the websites of US LCS programs with the Google internet search engine using the search terms lung cancer screening, low-dose CT screening, and lung screening. We used a standardized checklist to assess and collect specific content, including information regarding LCS staff composition and references to radiologists and radiology. We also tabulated types and frequencies of included multimedia and multilingual content and patient narratives. RESULTS: We analyzed 257 unique websites. Of these, only 48% (124 of 257) referred to radiologists or radiology in text, images, or videos. Radiologists were featured in images or videos on only 14% (36 of 257) of websites. Radiologists were most frequently acknowledged for their roles in reading or interpreting imaging studies (35% [90 of 574]). Regarding multimedia content, only 36% (92 of 257) of websites had 1 image, 27% (70 of 257) included 2 or more images, and 26% (68 of 257) of websites included one or more videos. Only 3% (7 of 257) of websites included information in a language other than English. Patient narratives were found on only 15% (39 of 257) of websites. CONCLUSIONS: The field of Radiology is mentioned in text, images, or videos by less than half of LCS program websites. Most websites make only minimal use of multimedia content such as images, videos, and patient narratives. Few websites provide LCS information in languages other than English, potentially limiting accessibility to diverse populations.


Subject(s)
Lung Neoplasms , Radiology , Early Detection of Cancer , Humans , Internet , Lung Neoplasms/diagnostic imaging , Multimedia , Search Engine , United States
SELECTION OF CITATIONS
SEARCH DETAIL